BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 37947028)

  • 1. The pan-Canadian Tiered Pricing Framework and Chinese National Volume-Based Procurement: A comparative study using Donabedian's structure-process-outcome framework.
    Wang Q; Liu S; Nie Z; Zhu Z; Fu Y; Zhang J; Wei X; Yang L; Wei X
    J Glob Health; 2023 Nov; 13():04137. PubMed ID: 37947028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Tiered-Pricing Framework on Generic Entry in Canada.
    Zhang W; Sun H; Guh DP; Lynd LD; Hollis A; Grootendorst P; Anis AH
    Int J Health Policy Manag; 2022 Jun; 11(6):768-776. PubMed ID: 33233033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of China's National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin.
    Zhao B; Wu J
    Int J Health Policy Manag; 2023; 12():7724. PubMed ID: 38618801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
    Roughead EE; Kim DS; Ong B; Kemp-Casey A
    WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of European pharmaceutical price regulation on generic price competition: a review.
    Puig-Junoy J
    Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving access to medicines and beyond: the national volume-based procurement policy in China.
    Zhu Z; Wang Q; Sun Q; Lexchin J; Yang L
    BMJ Glob Health; 2023 Jul; 8(7):. PubMed ID: 37463786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mixed integer programming model for vaccine pricing within a group purchasing organization.
    Yu Z; Keskinocak P; Orenstein WA; Toktay LB
    Vaccine; 2024 Mar; 42(8):1892-1898. PubMed ID: 37977944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of drug prices: a systematic review of comparison studies.
    Janssen Daalen JM; den Ambtman A; Van Houdenhoven M; van den Bemt BJF
    BMJ Open; 2021 Jul; 11(7):e046917. PubMed ID: 34266841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prices for generics in Australia - more competition might help.
    Bulfone L
    Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of volumes, prices and pricing trends of the pediatric antiretroviral market in developing countries from 2004 to 2012.
    Lee JSF; Sagaon Teyssier L; Dongmo Nguimfack B; Collins IJ; Lallemant M; Perriens J; Moatti JP
    BMC Pediatr; 2016 Mar; 16():41. PubMed ID: 26979974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement.
    Danzon PM; Mulcahy AW; Towse AK
    Health Econ; 2015 Feb; 24(2):238-52. PubMed ID: 24293058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling Tiered Pricing Frameworks: A Simulation Approach.
    Moradpour J; Zhang W; Grootendorst P; Anis AH; Hollis A
    Value Health; 2023 Mar; 26(3):351-358. PubMed ID: 36396022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
    Yıldız M; Osman E
    Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China.
    Yuan J; Lu ZK; Xiong X; Jiang B
    BMJ Glob Health; 2021 Sep; 6(9):. PubMed ID: 34518200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of National Volume-Based Procurement on the Procurement Volumes and Spending for Antiviral Medications of Hepatitis B Virus.
    Yuan J; Lu ZK; Xiong X; Lee TY; Huang H; Jiang B
    Front Pharmacol; 2022; 13():842944. PubMed ID: 35734415
    [No Abstract]   [Full Text] [Related]  

  • 18. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National Volume-Based Procurement (NVBP) exclusively for insulin: towards affordable access in China and beyond.
    Yuan J; Li M; Jiang X; Lu ZK
    BMJ Glob Health; 2024 Jan; 9(1):. PubMed ID: 38232994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
    Li DG; Joyce C; Mostaghimi A
    JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.